These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 2029695)

  • 21. No effect of chronic bromocriptine therapy on levodopa pharmacokinetics in patients with Parkinson's disease.
    Contin M; Riva R; Martinelli P; Albani F; Baruzzi A
    Clin Neuropharmacol; 1992 Dec; 15(6):505-8. PubMed ID: 1477850
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Brain dopamine receptor stimulation and the relief of Parkinsonism: relationship between bromocriptine and levodopa.
    Rinne UK; Marttila R
    Ann Neurol; 1978 Sep; 4(3):263-7. PubMed ID: 718139
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Correlation of the severity of autonomic dysfunction to cardiovascular reflexes and to plasma noradrenaline levels in Parkinson's disease.
    Turkka JT
    Eur Neurol; 1987; 26(4):203-10. PubMed ID: 3595658
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of levodopa alone and in combination with dopa-decarboxylase inhibitors on plasma renin activity in patients with Parkinson's disease.
    Rappelli A; Glorioso N; Tedde R; Dessi'-Fulgheri P; Monaco F
    J Neurol Neurosurg Psychiatry; 1978 Oct; 41(10):915-8. PubMed ID: 731241
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment of Parkinson's disease with dopamine agonists: a review.
    Lieberman A; Neophytides A; Kupersmith M; Casson I; Durso R; Foo SH; Khayali M; Tartaro T; Goldstein M
    Am J Med Sci; 1979; 278(1):65-76. PubMed ID: 39452
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Blood pressure adaptation and hormone regulation in Parkinson patients following orthostasis].
    Bellon AK; Jost WH; Schimrigk K; König J; Zeppezauer M
    Dtsch Med Wochenschr; 1996 Sep; 121(36):1077-83. PubMed ID: 8846752
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of the dopamine agonist bromocriptine on blood pressure, catecholamines and renin activity in acromegalics at rest, following exercise and during insulin induced hypoglycemia.
    Nilsson A; Hökfelt B
    Acta Endocrinol Suppl (Copenh); 1978; 216():83-96. PubMed ID: 274039
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cross tolerance between two dopaminergic ergot derivatives--bromocriptine and lergotrile.
    Teychenne PF; Rosin AJ; Plotkin CN; Calne DB
    Br J Clin Pharmacol; 1980 Jan; 9(1):47-50. PubMed ID: 6101955
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dopamine receptors: effects of chronic L-dopa and bromocriptine treatment in an animal model of Parkinson's disease.
    Schneider MB; Murrin LC; Pfeiffer RF; Deupree JD
    Clin Neuropharmacol; 1984; 7(3):247-57. PubMed ID: 6435870
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The influence of bromocriptine on the pharmacokinetics of levodopa in Parkinson's disease.
    Rabey JM; Schwartz M; Graff E; Harsat A; Vered Y
    Clin Neuropharmacol; 1991 Dec; 14(6):514-22. PubMed ID: 1773422
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Parkinson-Control study: a 1-year randomized, double-blind trial comparing piribedil (150 mg/day) with bromocriptine (25 mg/day) in early combination with levodopa in Parkinson's disease.
    Castro-Caldas A; Delwaide P; Jost W; Merello M; Williams A; Lamberti P; Aguilar M; Del Signore S; Cesaro P;
    Mov Disord; 2006 Apr; 21(4):500-9. PubMed ID: 16267842
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of bromocriptine on plasma catecholamines in normal men.
    Van Loon GR; Sole MJ; Bain J; Ruse JL
    Neuroendocrinology; 1979; 28(6):425-34. PubMed ID: 460538
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ropinirole as an adjunct to levodopa in the treatment of Parkinson's disease: a 16-week bromocriptine controlled study.
    Im JH; Ha JH; Cho IS; Lee MC
    J Neurol; 2003 Jan; 250(1):90-6. PubMed ID: 12527999
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparisons of therapeutic effects of levodopa, levodopa and selegiline, and bromocriptine in patients with early, mild Parkinson's disease: three year interim report. Parkinson's Disease Research Group in the United Kingdom.
    BMJ; 1993 Aug; 307(6902):469-72. PubMed ID: 8400928
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bromocriptine versus levodopa in early Parkinson's disease.
    Ramaker C; van Hilten JJ
    Cochrane Database Syst Rev; 2000; (3):CD002258. PubMed ID: 10908538
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The acute and chronic effects of nitrendipine on plasma catecholamines in hypertensive patients.
    el-Beheiry H; Ruedy N; Wall RA; Murphy M; Wright JM
    Can J Cardiol; 1993; 9(1):41-6. PubMed ID: 8439828
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The influence of levodopa in the pharmacokinetics of bromocriptine in Parkinson's disease.
    Rabey JM; Oberman Z; Scharf M; Isakov A; Bar M; Graff E
    Clin Neuropharmacol; 1989 Oct; 12(5):440-7. PubMed ID: 2611767
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bromocriptine alone or associated with L-dopa plus benserazide in Parkinson's disease.
    Caraceni TA; Celano I; Parati E; Girotti F
    J Neurol Neurosurg Psychiatry; 1977 Dec; 40(12):1142-6. PubMed ID: 591982
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The pharmacology of Parkinson's disease: basic aspects and recent advances.
    Da Prada M; Keller HH; Pieri L; Kettler R; Haefely WE
    Experientia; 1984 Nov; 40(11):1165-72. PubMed ID: 6437857
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of subthalamic nucleus stimulation and levodopa on the autonomic nervous system in Parkinson's disease.
    Ludwig J; Remien P; Guballa C; Binder A; Binder S; Schattschneider J; Herzog J; Volkmann J; Deuschl G; Wasner G; Baron R
    J Neurol Neurosurg Psychiatry; 2007 Jul; 78(7):742-5. PubMed ID: 17371906
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.